NZ629453A - Thiazole derivatives as alpha 7 nachr modulators - Google Patents
Thiazole derivatives as alpha 7 nachr modulatorsInfo
- Publication number
- NZ629453A NZ629453A NZ629453A NZ62945313A NZ629453A NZ 629453 A NZ629453 A NZ 629453A NZ 629453 A NZ629453 A NZ 629453A NZ 62945313 A NZ62945313 A NZ 62945313A NZ 629453 A NZ629453 A NZ 629453A
- Authority
- NZ
- New Zealand
- Prior art keywords
- benzenesulfonamide
- thiazol
- compounds
- chlorophenyl
- carbonyl
- Prior art date
Links
- 150000007979 thiazole derivatives Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- IFKBWQYSWMSHJE-IYBDPMFKSA-N 4-[4-(1-acetyl-2,3-dihydroindol-5-yl)-2-[(2s,6r)-2,6-dimethylmorpholine-4-carbonyl]-1,3-thiazol-5-yl]benzenesulfonamide Chemical compound C1[C@@H](C)O[C@@H](C)CN1C(=O)C1=NC(C=2C=C3CCN(C3=CC=2)C(C)=O)=C(C=2C=CC(=CC=2)S(N)(=O)=O)S1 IFKBWQYSWMSHJE-IYBDPMFKSA-N 0.000 abstract 1
- QHFAVPQTOJLULP-UHFFFAOYSA-N 4-[4-(4-chloro-3-methylphenyl)-2-(pyrrolidine-1-carbonyl)-1,3-thiazol-5-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(C)=CC(C2=C(SC(=N2)C(=O)N2CCCC2)C=2C=CC(=CC=2)S(N)(=O)=O)=C1 QHFAVPQTOJLULP-UHFFFAOYSA-N 0.000 abstract 1
- CPZJSIJYUXTCJT-UHFFFAOYSA-N 4-[4-(4-chlorophenyl)-2-(4-methylpiperazin-1-yl)-1,3-thiazol-5-yl]benzenesulfonamide Chemical compound C1CN(C)CCN1C1=NC(C=2C=CC(Cl)=CC=2)=C(C=2C=CC(=CC=2)S(N)(=O)=O)S1 CPZJSIJYUXTCJT-UHFFFAOYSA-N 0.000 abstract 1
- HQQDTFLZRUUATI-UHFFFAOYSA-N 4-[4-(4-chlorophenyl)-2-morpholin-4-yl-1,3-thiazol-5-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C1=C(C=2C=CC(Cl)=CC=2)N=C(N2CCOCC2)S1 HQQDTFLZRUUATI-UHFFFAOYSA-N 0.000 abstract 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 abstract 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 abstract 1
- 206010039966 Senile dementia Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000027061 mild cognitive impairment Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN235KO2012 | 2012-03-06 | ||
| IN236KO2012 | 2012-03-06 | ||
| IN237KO2012 | 2012-03-06 | ||
| IN1307KO2012 | 2012-11-12 | ||
| PCT/IB2013/051455 WO2013132380A1 (en) | 2012-03-06 | 2013-02-22 | Thiazole derivatives as alpha 7 nachr modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ629453A true NZ629453A (en) | 2016-04-29 |
Family
ID=54261190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ629453A NZ629453A (en) | 2012-03-06 | 2013-02-22 | Thiazole derivatives as alpha 7 nachr modulators |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9388196B2 (enExample) |
| EP (1) | EP2822946A1 (enExample) |
| AU (1) | AU2013229177B2 (enExample) |
| CA (1) | CA2866015A1 (enExample) |
| IN (1) | IN2014MN01756A (enExample) |
| NZ (1) | NZ629453A (enExample) |
| SG (1) | SG11201405239WA (enExample) |
| WO (1) | WO2013132380A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101742954B1 (ko) * | 2012-05-31 | 2017-06-02 | 페넥스 파마슈티컬스 아게 | 고아 핵 수용체 ror[감마]의 조절제로서의 카복사미드 또는 설폰아미드가 치환된 티아졸 및 관련된 유도체 |
| EP2945936A1 (en) * | 2012-11-12 | 2015-11-25 | Lupin Limited | Thiazole derivatives as alpha 7 nachr modulators |
| AU2014229300A1 (en) | 2013-03-13 | 2015-06-11 | Lupin Limited | Pyrrole derivatives as alpha 7 nAChR modulators |
| TW201446243A (zh) | 2013-06-03 | 2014-12-16 | Lupin Ltd | 4-(5-(4-氯苯基)-2-(2-環丙基乙醯基)-1,4-二甲基-1氫-吡咯-3-基)苯磺醯胺作為α7尼古丁乙醯膽鹼受體調節劑 |
| WO2014203150A1 (en) | 2013-06-17 | 2014-12-24 | Lupin Limited | Pyrrole derivatives as alpha 7 nachr modulators |
| SG11201610975RA (en) * | 2014-07-03 | 2017-01-27 | Celgene Quanticel Res Inc | Inhibitors of lysine specific demethylase-1 |
| EP3623371A1 (en) | 2014-12-16 | 2020-03-18 | Axovant Sciences GmbH | Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors |
| CA2988968A1 (en) | 2015-06-10 | 2016-12-15 | Forum Pharmaceuticals, Inc. | Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors |
| CA3030582A1 (en) * | 2015-07-22 | 2017-01-26 | The Royal Institution For The Advancement Of Learning/Mcgill University | Compounds and uses thereof in the treatment of cancers and other medical conditions |
| JP2018523707A (ja) | 2015-08-12 | 2018-08-23 | アクソバント サイエンシズ ゲーエムベーハー | α７−ニコチン性アセチルコリン受容体のアゴニストとしてのジェミナル置換アミノベンゾイソオキサゾール化合物 |
| CN108101860B (zh) * | 2018-02-08 | 2021-11-23 | 苏州敬业医药化工有限公司 | 顺式-2，6-二甲基吗啉的制备方法 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3953596A (en) | 1973-06-14 | 1976-04-27 | Ici United States Inc. | 8-Oxa-3-azabicyclo(3.2.1)octane analgesic compositions and method of alleviating pain in animals |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| JPH10504542A (ja) * | 1994-07-27 | 1998-05-06 | ジー．ディー．サール アンド カンパニー | 炎症処置用の置換チアゾール化合物 |
| US5608082A (en) | 1994-07-28 | 1997-03-04 | Agouron Pharmaceuticals, Inc. | Compounds useful as antiproliferative agents and GARFT inhibitors |
| ATE273279T1 (de) | 1997-09-12 | 2004-08-15 | Merck Frosst Canada Inc | 2,3,5-trisubstituierte pyridine als inhibitoren von cyclooxygenase-2 |
| KR100926839B1 (ko) | 2002-02-01 | 2009-11-12 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | ２－퓨란 카르복시산 하이드라지드 화합물 및 그것을함유하는 의약 조성물 |
| US7202367B2 (en) | 2002-05-31 | 2007-04-10 | Rhodia Chimie | Process for arylating or vinylating or alkynating a nucleophilic compound |
| SE0201938D0 (sv) | 2002-06-20 | 2002-06-20 | Astrazeneca Ab | New process |
| DE10244810A1 (de) | 2002-09-26 | 2004-04-08 | Bayer Ag | Neue Morpholin-überbrückte Indazolderivate |
| US7129235B2 (en) | 2003-07-11 | 2006-10-31 | Abbott Laboratories | Amides useful for treating pain |
| US7442805B2 (en) | 2003-09-25 | 2008-10-28 | Wyeth | Substituted sulfonamide-indoles |
| GB0403038D0 (en) | 2004-02-11 | 2004-03-17 | Novartis Ag | Organic compounds |
| WO2005092843A1 (en) | 2004-03-29 | 2005-10-06 | Neurosearch A/S | Novel urea derivatives and their medical use |
| ITTO20040264A1 (it) | 2004-04-28 | 2004-07-28 | Rotta Res Lab Spa | Nuovi derivati pirrolici ad attivita' angiotensina-ii antagonista |
| EP1790640A4 (en) | 2004-09-09 | 2009-07-29 | Chugai Pharmaceutical Co Ltd | NEW IMIDAZOLIDINE DERIVATIVE AND APPLICATION THEREOF |
| US20060142349A1 (en) | 2004-12-23 | 2006-06-29 | Pfizer Inc | Methods of modulating the activities of alpha-7 nicotinic acetylcholine receptor |
| US7750011B2 (en) | 2005-02-15 | 2010-07-06 | Neurosearch A/S | Diazabicyclic aryl derivatives and their medical use |
| FR2885616B1 (fr) | 2005-05-12 | 2007-06-22 | Servier Lab | Nouveaux derives de phenylpyridinylpiperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CA2617788A1 (en) | 2005-08-04 | 2007-02-15 | Apogee Biotechnology Corporation | Sphingosine kinase inhibitors and methods of their use |
| NZ566036A (en) | 2005-09-13 | 2010-06-25 | Janssen Pharmaceutica Nv | 2-Aniline-4-aryl substituted thiazole derivatives that modulate the alpha7 nicotinic receptor |
| EP1984360B1 (en) | 2006-02-03 | 2014-01-15 | Eli Lilly & Company | Compounds and methods for modulating FX-receptors |
| JP2009526814A (ja) | 2006-02-16 | 2009-07-23 | ノイロサーチ アクティーゼルスカブ | 鏡像異性的に純粋なキヌクリジニルオキシピリダジン、及びニコチン性アセチルコリン受容体リガンドとしてのその使用 |
| JO3019B1 (ar) | 2006-04-19 | 2016-09-05 | Janssen Pharmaceutica Nv | ثلاثي مستبدل 4،2،1-ثلاثي زولات |
| BRPI0712667A2 (pt) | 2006-06-27 | 2012-09-04 | Abbott Lab | derivados do pirrol e seus métodos de uso |
| WO2008002956A2 (en) | 2006-06-27 | 2008-01-03 | Abbott Laboratories | Thiazoline and oxazoline derivatives and their methods of use |
| US20100069347A1 (en) | 2006-11-02 | 2010-03-18 | Morriello Gregori J | Heterocyclyl-substituted anti-hypercholesterolemic compounds |
| US20080287479A1 (en) | 2006-12-20 | 2008-11-20 | Pfizer Inc | Inhibitors of serine palmitoyltransferase |
| MX2010001135A (es) | 2007-08-08 | 2010-03-09 | Neurosearch As | Nuevos derivados de 1,2,3-triazol, utiles como modulares de receptores de acetilcolina nicotinicos. |
| GB0718735D0 (en) | 2007-09-25 | 2007-11-07 | Prolysis Ltd | Antibacterial agents |
| WO2009043784A1 (en) | 2007-10-04 | 2009-04-09 | F. Hoffmann-La Roche Ag | Cyclopropyl aryl amide derivatives and uses thereof |
| KR101186704B1 (ko) | 2007-10-04 | 2012-09-27 | 에프. 호프만-라 로슈 아게 | 테트라졸-치환된 아릴 아마이드 유도체 및 이의 용도 |
| JO2784B1 (en) | 2007-10-18 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | 5,3,1 - Triazole substitute derivative |
| MY152486A (en) | 2008-03-19 | 2014-10-15 | Janssen Pharmaceutica Nv | Trisubstituted 1,2,4 - triazoles as nicotinic acetylcholine receptor modulators |
| US7786171B2 (en) | 2008-04-04 | 2010-08-31 | Abbott Laboratories | Amide derivatives as positive allosteric modulators and methods of use thereof |
| UY31769A1 (es) | 2008-04-17 | 2009-09-30 | Derivados del indol con actividad modulatoria del receptor nicotínico de acetilcolina | |
| US8779158B2 (en) | 2008-05-09 | 2014-07-15 | Janssen Pharmaceutica Nv | Trisubstituted pyrazoles as acetylcholine receptor modulators |
| US8563579B2 (en) | 2009-01-15 | 2013-10-22 | Anvyl Llc | α-7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof |
| WO2010120854A1 (en) | 2009-04-15 | 2010-10-21 | Glaxosmithkline Llc | Chemical compounds |
| US20120071469A1 (en) | 2009-05-14 | 2012-03-22 | Neurosearch A/S | Novel 1,4-diaza-bicyclo[3.2.1]octane derivatives useful as nicotinic acetylcholine receptor modulators |
| JO3250B1 (ar) | 2009-09-22 | 2018-09-16 | Novartis Ag | إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7 |
| JO3078B1 (ar) * | 2009-11-27 | 2017-03-15 | Janssen Pharmaceutica Nv | مورفولينوثيازولات بصفتها منظمات الوستيرية نوع الفا 7 موجبة |
| MX344701B (es) | 2011-02-03 | 2017-01-03 | Lupin Ltd | Derivados de pirrol como moduladores de nachr alfa 7. |
| KR20140026378A (ko) | 2011-02-23 | 2014-03-05 | 루핀 리미티드 | 알파 7 ｎａｃｈｒ 조절자로서 헤테로아릴 유도체 |
| SG193387A1 (en) | 2011-03-31 | 2013-10-30 | Lupin Ltd | Pyrrole derivatives as nicotinic acetylcholine receptor modulators for use in the treatment of neurodegenerative disorders such as alzheimer's and parkinson's disease |
| ES2606043T3 (es) | 2011-07-05 | 2017-03-17 | Lupin Limited | Derivados de biarilo como moduladores de nAChR |
-
2013
- 2013-02-22 WO PCT/IB2013/051455 patent/WO2013132380A1/en not_active Ceased
- 2013-02-22 AU AU2013229177A patent/AU2013229177B2/en not_active Expired - Fee Related
- 2013-02-22 EP EP13711972.3A patent/EP2822946A1/en not_active Withdrawn
- 2013-02-22 US US14/379,134 patent/US9388196B2/en not_active Expired - Fee Related
- 2013-02-22 SG SG11201405239WA patent/SG11201405239WA/en unknown
- 2013-02-22 CA CA2866015A patent/CA2866015A1/en not_active Abandoned
- 2013-02-22 IN IN1756MUN2014 patent/IN2014MN01756A/en unknown
- 2013-02-22 NZ NZ629453A patent/NZ629453A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2866015A1 (en) | 2013-09-12 |
| WO2013132380A1 (en) | 2013-09-12 |
| US20150291617A1 (en) | 2015-10-15 |
| IN2014MN01756A (enExample) | 2015-07-03 |
| SG11201405239WA (en) | 2014-09-26 |
| US9388196B2 (en) | 2016-07-12 |
| EP2822946A1 (en) | 2015-01-14 |
| AU2013229177A1 (en) | 2014-09-18 |
| AU2013229177B2 (en) | 2017-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ629453A (en) | Thiazole derivatives as alpha 7 nachr modulators | |
| FI3406609T3 (fi) | Bisyklisiä atsayhdisteitä muskariinireseptorin agonisteina | |
| PH12020551870A1 (en) | Tetracyclic heteroaryl compounds | |
| MX2022012317A (es) | Oxisteroles y metodos de uso de los mismos. | |
| PH12019500830A1 (en) | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer | |
| PH12013501727A1 (en) | Heteroaryl derivatives as alpha7 nachr modulators | |
| MY195742A (en) | Isoindoline-1-One Derivatives as Cholinergic Muscarinic M1 Receptor Positive Alloesteric Modulator Activity for the Treatment of Alzheimers Disease | |
| SG10201906942PA (en) | Piperidine cxcr7 receptor modulators | |
| RU2013138733A (ru) | Конденсированные производные аминодигидротиазина | |
| WO2018042362A9 (en) | Muscarinic m1 receptor positive allosteric modulators | |
| CN110770233A (zh) | 稠合双环类化合物及其在药物中的应用 | |
| MX344696B (es) | Derivados de pirrol como moduladores de los receptores de acetilcolina nicotinicos para su uso en el tratamiento de enfermedades neurodegenerativas como el alzheimer y la enfermedad de parkinson. | |
| SI2875011T1 (en) | 5-HT3 receptor antagonists | |
| MD20160105A2 (ro) | 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide | |
| TW201613890A (en) | Pyridine derivatives as muscarinic M1 receptor positive allosteric modulators | |
| MY183111A (en) | 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators | |
| MX2013008056A (es) | 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2). | |
| WO2013188283A8 (en) | Topical ophthalmological pharmaceutical composition containing sunitinib | |
| PH12017502254A1 (en) | Pyrazole derivative or pharmaceutically acceptable salt thereof | |
| WO2009140341A3 (en) | Atorvastatin compositions | |
| PH12014502541A1 (en) | 5-amino [1,4] thiazines as bace 1 inhibitors | |
| UA117154C2 (uk) | Антагоністи s1p3 | |
| EP4494705A3 (en) | Non-peptide oxytocin receptor agonists | |
| MY193041A (en) | Novel fused imidazobenzothiazole compounds | |
| WO2014014794A3 (en) | Mineralocorticoid receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 FEB 2018 BY WRAYS Effective date: 20161122 |
|
| LAPS | Patent lapsed |